Inhibikase Therapeutics, Inc. — FY2021 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2021; filed March 31, 2022. The filing reports annual results, not a standalone fourth-quarter filing. Inhibikase is a clinical-stage pharmaceutical company with no approved products or commercial product revenue.
Business Context and Development Status
- Lead candidate IkT-148009 is an oral, brain-penetrant c-Abl inhibitor being developed for Parkinson’s disease and gastrointestinal complications associated with Parkinson’s disease.
- The Phase 1 SAD/MAD study in older and elderly healthy volunteers enrolled 88 subjects. Management reported a half-life exceeding 24 hours and exposure consistent with efficacious animal-model dosing at a 25 mg once-daily dose.
- Phase 1b dosing in Parkinson’s patients began October 19, 2021; one eight-patient cohort had completed the study by the filing date.
- IkT-148009 is also being evaluated for Multiple System Atrophy, subject to favorable animal-model results and regulatory discussions.
- IkT-001Pro, a prodrug of imatinib for stable-phase chronic myelogenous leukemia, completed clinical batch manufacturing in late 2021. The company planned an IND submission in the second quarter of 2022 and expects to pursue the FDA’s Section 505(b)(2) pathway.
Financial Performance and Liquidity
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Grant revenue | $3.1 million | $0.7 million | +$2.4 million |
| Research and development expense | $11.4 million | $0.9 million | +$10.5 million |
| Selling, general and administrative expense | $6.5 million | $2.6 million | +$3.9 million |
| Loss from operations | $(14.8) million | $(2.8) million | Loss increased |
| Net loss | $(14.8) million | $(2.8) million | Loss increased by $11.9 million |
| Basic and diluted net loss per share | $(0.81) | $(0.35) | Worsened |
| Net cash used in operating activities | $(14.3) million | $(1.1) million | Higher cash burn |
| Net cash provided by financing activities | $41.1 million | $15.1 million | Primarily equity offerings |
- At December 31, 2021, cash was $40.8 million, working capital was $38.4 million, total assets were $42.5 million, and total liabilities were $4.1 million.
- Accumulated deficit was $29.8 million. The company has generated no product-sales revenue and expects continued operating losses.
- Debt was limited primarily to a $248,911 CEO note outstanding at year-end; it was repaid in full on January 3, 2022. The $27,550 PPP loan was forgiven in 2021.
- June 2021’s public offering of 15.0 million shares generated approximately $41.1 million of net proceeds. The company also received approximately $14.6 million of net proceeds from its December 2020 IPO.
- Management estimated that available working capital would fund normal operations into the third quarter of 2023, but stated that additional capital will be needed to continue current clinical trials and planned programs beyond that point.
- The company had $385,888 of active grant funding available as of March 14, 2022. More than 90% of revenue in both 2021 and 2020 came from the U.S. government through federal research grants.
Material Changes Versus 2020
- Grant revenue increased 343.9% to $3.1 million, driven by greater grant-funded research activity.
- Research and development expense increased more than elevenfold, primarily due to the Phase 1 Parkinson’s trial and increased grant-related research.
- SG&A increased 148.1%, reflecting higher directors’ and officers’ insurance, legal and professional fees, public-company costs, administrative wages and investor-relations expenses.
- Operating cash burn increased substantially as clinical development accelerated.
- Common shares outstanding increased from 10.1 million at December 31, 2020 to 25.2 million at December 31, 2021, primarily due to the June 2021 equity offering, creating significant dilution for existing holders.
- The company moved from primarily grant-funded operations toward a combination of grants and public-equity financing.
Guidance, Outlook, Risks and Unusual Items
- Management expected to report full Phase 1 results, complete chronic toxicology studies, complete a Phase 1b extension study and initiate a Phase 2a Parkinson’s study in 2022, subject to FDA review and agreement.
- A Phase 2a Multiple System Atrophy study was targeted for the third quarter of 2022, contingent on positive animal-model results and regulatory agreements in the U.S. and Europe. The study would not proceed if the model results were unsuccessful.
- The company planned to submit the IkT-001Pro IND in the second quarter of 2022 and begin clinical development shortly thereafter. These milestones were plans, not assurances.
- Preclinical results have not established that IkT-148009 will halt or reverse disease progression in humans. The company expressly states that it has not observed reversal of functional loss in humans.
- Key risks include failure to demonstrate clinical efficacy or safety, regulatory delays or rejection, clinical-trial enrollment and execution problems, COVID-19-related disruptions, reliance on third-party CROs and manufacturers, supply-chain exposure including manufacturers in China, competition, intellectual-property challenges and the need for additional financing.
- The company depends on equity offerings, grants, debt or collaborations to fund operations. Additional financing may be unavailable or dilutive, and management has no committed source of future capital.
- The company’s financial statements were prepared on a going-concern basis. There was no material litigation reported at the filing date, and no off-balance-sheet arrangements were disclosed.
- The filing disclosed a March 2022 increase in CEO base salary to $510,000 and target bonus to 50%, and an increase in CFO base salary to $400,000 and target bonus to 40%, together with additional option grants.
Investor Verification Checklist
- Verify the complete Phase 1 and Phase 1b safety, pharmacokinetic and efficacy data for IkT-148009, including adverse events and cerebrospinal-fluid exposure.
- Verify whether the FDA agreed to the proposed Phase 2a Parkinson’s and Multiple System Atrophy protocols and whether the planned enrollment and timing were achieved.
- Verify submission and acceptance of the IkT-001Pro IND and the FDA’s treatment of the proposed Section 505(b)(2) pathway.
- Reconcile cash burn against the company’s projected third-quarter 2023 funding runway and assess the timing, terms and dilution of any future financing.
- Review grant concentration, grant renewal prospects and restrictions on the use of remaining grant funds.
- Assess third-party manufacturing capacity, supply-chain concentration and the status of alternative suppliers.
- Review patent ownership, co-development rights and the renegotiation of financial obligations with Sphaera Pharma.
- Monitor whether preclinical disease-modification claims translate into statistically significant human clinical benefit.